Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
5/6/24 | ADC Therapeutics (ADCT) | Zynlonta for Marginal Zone Lymphoma - NHL | Subscribers Only | Subscribers Only | Subscribers Only |
5/6/24 | GlycoMimetics (GLYC) | Uproleselan for Acute Myelogenous Leukemia (AML) | Subscribers Only | Subscribers Only | Subscribers Only |
5/6/24 | ImPact Biotech | Tookad for Bladder Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
5/6/24 | Lyra Therapeutics (LYRA) | LYR-210 for Chronic Rhinosinusitis | Subscribers Only | Subscribers Only | Subscribers Only |
5/2/24 | Organogenesis (ORGO) | ReNu for Osteoarthritis | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
03/19/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
04/09/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
04/15/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
04/15/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
04/18/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |